Elizabeth E. Reed's Insider Trades & SAST Disclosures
Elizabeth E. Reed's most recent trade in Travere Therapeutics Inc was a trade of 4,920 Performance-based restricted stock units done . Disclosure was reported to the exchange on May 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Elizabeth E. Reed.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 4,920 | 4,920 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 02 May 2025 | 4,920 | 89,482 (0%) | 0% | 21.1 | 103,566 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 4,920 | 94,402 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 0 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 97,482 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 23.53 per share. | 10 Feb 2025 | 8,000 | 89,482 (0%) | 0% | 23.5 | 188,240 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 58,000 | 58,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 21,500 | 98,433 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 19.78 per share. | 31 Jan 2025 | 8,951 | 89,482 (0%) | 0% | 19.8 | 177,051 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 19.46 per share. | 22 Jan 2025 | 2,437 | 76,933 (0%) | 0% | 19.5 | 47,424 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2024 | 6,750 | 83,020 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 11.52 per share. | 05 Sep 2024 | 4,387 | 78,633 (0%) | 0% | 11.5 | 50,538 | Common Stock |
| Travere Therapeutics Inc | Reed E. Elizabeth | SVP, GC & CORPORATE SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 65,000 | 65,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Reed Elizabeth E. | SVP, GC & CORPORATE SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 25,000 | 81,034 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | E. Elizabeth Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 8.86 per share. | 31 Jan 2024 | 2,590 | 76,270 (0%) | 0% | 8.9 | 22,947 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 31 Jan 2024 | 2,174 | 78,860 (0%) | 0% | 8.5 | 18,548 | Common Stock |
| Travere Therapeutics Inc | E. Elizabeth Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 8.96 per share. | 23 Jan 2024 | 2,062 | 56,034 (0%) | 0% | 9.0 | 18,476 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 16.59 per share. | 10 May 2023 | 825 | 56,611 (0%) | 0% | 16.6 | 13,687 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 54,500 | 54,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 20,250 | 60,026 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 6,750 | 6,750 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 22.25 per share. | 31 Jan 2023 | 2,590 | 57,436 (0%) | 0% | 22.3 | 57,628 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 24 Jan 2023 | 2,062 | 39,776 (0%) | 0% | 21.5 | 44,333 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 21.51 per share. | 10 May 2022 | 1,050 | 41,838 (0%) | 0% | 21.5 | 22,584 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 21.51 per share. | 10 May 2022 | 900 | 42,888 (0%) | 0% | 21.5 | 19,359 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 39,360 | 39,360 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 9,840 | 9,840 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 9,840 | 45,138 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 8,000 | 8,000 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 27.40 per share. | 31 Jan 2022 | 1,350 | 43,788 (0%) | 0% | 27.4 | 36,990 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 24.98 per share. | 24 Jan 2022 | 2,250 | 35,298 (0%) | 0% | 25.0 | 56,205 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 27.40 per share. | 10 Jan 2022 | 5,000 | 37,548 (0%) | 0% | 27.4 | 137,000 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 5,000 | 42,548 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 4,500 | 38,955 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 17.12 per share. | 13 Aug 2021 | 1,407 | 37,548 (0%) | 0% | 17.1 | 24,086 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 19.46 per share. | 11 May 2021 | 1,625 | 34,455 (0%) | 0% | 19.5 | 31,623 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 19.14 per share. | 11 May 2021 | 1,625 | 36,080 (0%) | 0% | 19.1 | 31,103 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 31.58 per share. | 05 Feb 2021 | 2,250 | 37,705 (0%) | 0% | 31.6 | 71,055 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 31.41 per share. | 05 Feb 2021 | 2,250 | 39,955 (0%) | 0% | 31.4 | 70,673 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 4,500 | 42,205 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 28.91 per share. | 03 Feb 2021 | 2,500 | 38,380 (0%) | 0% | 28.9 | 72,275 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 28.91 per share. | 03 Feb 2021 | 675 | 37,705 (0%) | 0% | 28.9 | 19,514 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 5,000 | 44,055 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 31 Jan 2021 | 2,500 | 41,555 (0%) | 0% | 30.8 | 76,875 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 31 Jan 2021 | 675 | 40,880 (0%) | 0% | 30.7 | 20,756 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 57,500 | 57,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 15,000 | 39,055 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 26.65 per share. | 05 Jan 2021 | 688 | 24,743 (0%) | 0% | 26.6 | 18,335 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 27.01 per share. | 05 Jan 2021 | 688 | 24,055 (0%) | 0% | 27.0 | 18,583 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 23.98 per share. | 16 Nov 2020 | 2,500 | 25,431 (0%) | 0% | 24.0 | 59,950 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2020 | 5,000 | 30,431 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 23.62 per share. | 11 Nov 2020 | 2,500 | 27,931 (0%) | 0% | 23.6 | 59,046 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 18.48 per share. | 23 Sep 2020 | 1,500 | 25,431 (0%) | 0% | 18.5 | 27,720 | Common Stock |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2020 | 3,000 | 28,431 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 18.59 per share. | 18 Sep 2020 | 1,500 | 26,931 (0%) | 0% | 18.6 | 27,885 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges